It’s not an immunity passport
I have had discussions lately about the perception that an immunity passport is the same as a vaccination passport. This […]
Blue Steens in June 2020
Check out my latest monthly review! It showcases Blue Steens’ latest posts, some news from biopharma & medtech as well […]
Daclizumab – Manipulating the immune system in unexpected ways
Daclizumab, marketed as Zinbryta, was approved for the treatment of relapsing-remitting multiple sclerosis (MS) in the USA and Europe in summer 2016. Daclizumab has shown […]